|
KMID : 1103920080140040493
|
|
Korean Journal of Hepatology
2008 Volume.14 No. 4 p.493 ~ p.502
|
|
|
Efficacy of initial treatment with peginterferon alpha-2a versus peginterferon alpha-2b in combination with ribavirin in naive chronic hepatitis C patients Living in Daejeon and Chungcheong Province in Korea: A comparative study
|
|
Kim Jung-Il
Lee Tae-Hee
Kang Young-Woo
Nam Soon-Woo
Lee Heon-Young
Song Il-Han
Kim Seok-Hyun
Lee Byung-Seok
Kim An-Na
Park Byeong-Chool
Chae Hee-Bok
Kim Suk-Bae
Park Ji-Young
Lee Hyang-Yi
Kim Hong-Soo
|
|
|
Abstract
|
|
|
Backgrounds/Aims: Peginterferon alpha-2a or -2b is the standard treatment regimen in chronic hepatitis C. However, there have been few comparative studies of the efficacies of these two types of peginterferon. We evaluated their efficacies in combination with ribavirin as a initial treatment for chronic hepatitis C.
Methods: Ninety-seven patients were treated with peginterferon alpha-2a (180 ?g/week, n=48) or peginterferon alpha-2b(1.5 ?g/kg/week, n=49) plus ribavirin (800 mg/day for 24 weeks in genotype non-1 or 1,000-1,200 mg/day for 48 weeks in genotype 1). Virologic responses including the early virologic response (EVR), end-of-treatment response (ETR), sustained virologic response (SVR), and adverse effects were analyzed retrospectively.
Results: The virologic response rates did not differ significantly between peginterferon alpha-2a and -2b: 89.6% and 89.7% for EVR, 79.2% and 79.5% for ETR, 72.9% and 73.5% for SVR, respectively. Analysis of the virologic responses according to genotype also revealed no significant differences in SVR between peg-interferon alpha-2a and -2b (59.3% vs. 59.7% for genotype 1 and 90.5% vs. 83.3% for genotype non-1, respectively), or in adverse effects including flu-like symptom, rash, itching, neutropenia, and thrombocytopenia.
Conclusions: We found no significant differences in therapeutic efficacies and adverse effects between the alpha-2a and -2b types of peginterferon as the initial treatment regimen in naive chronic hepatitis C patients.
|
|
|
KEYWORD
|
|
|
Peginterferon, Ribavirin, Efficacy, Adverse effects, Hepatitis C
|
|
|
FullTexts / Linksout information
|
|
 
|
|
|
Listed journal information
|
|
   
|
|